Researchers examine unanticipated benefits of GLP-1 medications
GLP-1 receptor agonists and dual agonists have transformed the treatment of obesity and other metabolic diseases, and a new editorial co-authored by Dr. Steven Heymsfield of LSU's Pennington Biomedical Research Center and Dr. Adam Gilden of the University of Colorado examines what scientists are learning as these medications reach millions of people.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
